Board of Directors
The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.
Daniel J. Moore (Chairman)
Daniel Moore is Chairman of the Board for LivaNova [NASDAQ: LIVN]. Mr. Moore previously held the position as president and chief executive officer of Cyberonics [NASDAQ: CYBX] from 2007 to 2015, when the company merged with Sorin to form LivaNova. Mr. Moore joined Cyberonics after 18 years at Boston Scientific [NYSE: BSX] where he was the president of InterContinental. He also serves on the boards of the Epilepsy Foundation of America, BioHouston and the Advisory Board of Purdue University’s Weldon School of Biomedical Engineering.
Prior company boards include TriVascular [NASDAQ: TRIV] which was sold to Endologix and Topera which was sold to Abbott. He also served on the boards of BrainScope Company, Inc., Medical Device Manufacturers Association (past-Chair), Medical Device Innovation Consortium, Epilepsy Foundation of Texas (past- Chair) and Smiling Kids Inc.
Oern Stuge, MD, MBA
Oern Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.
Juliet Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dynamics, Ms. Thompson also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.
Praveen Tyle, PhD
Praveen Tyle, PhD, brings extensive knowledge in research and development from the pharmaceutical, consumer health, and medical device industry.
Dr. Tyle is currently the executive vice president of research and development at Lexicon. He previously held the position as member of the executive management team for Osmotica Pharmaceutical Corp., where his last held position was president and chief executive officer, prior to that he served as executive vice president and chief scientific officer.
Prior to Osmotica, Dr. Tyle held a series of scientific leadership positions within the pharmaceutical industry, with the United States Pharmacopeia, Novartis OTC, Bausch & Lomb Incorporated and Pharmacia Corporation. Dr. Tyle also serves as director of Eyegate Pharmaceuticals, Inc. and Orient Europharma Ltd.
Dr. Tyle received his B.Pharm. (honors) from the Indian Institute of Technology, Banaras Hindu University and his PhD in pharmaceutics and pharmaceutical chemistry from the Ohio State University.